Celltrion Pharm Inc.
068760 | KO
Overview
Corporate Details
- ISIN(s):
- KR7068760008
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청주시 청원구 오창읍 2산단로 82셀트리온제약, 청주시
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-29 00:00 |
Governance Information
대규모기업집단현황공시[분기별공시(개별회사용)]
|
Korean | 8.9 KB | ||
| 2025-08-14 00:00 |
Regulatory Filings
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
|
Korean | 11.1 KB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 2.6 MB | ||
| 2025-06-23 00:00 |
Major Shareholding Notification
[기재정정]대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 135.3 KB | ||
| 2025-05-30 00:00 |
Major Shareholding Notification
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
|
Korean | 100.8 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.4 MB | ||
| 2025-05-07 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 25.8 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-10 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 252.0 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.9 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB | ||
| 2025-04-04 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.1 KB |
Automate Your Workflow. Get a real-time feed of all Celltrion Pharm Inc. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Celltrion Pharm Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Celltrion Pharm Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Develops topical skin treatments by reformulating drugs with a lipid-based delivery platform.
Sweden
LIPI
Sweden
LIPI
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
United States of America
LPCN
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
United States of America
LQDA
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
United States of America
LSTA
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
United States of America
LGVN
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Switzerland
LONN
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
United States of America
LYEL
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
United States of America
LYRA
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
Norway
LYTIX
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
Poland
MAB